Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Vaccine

New Jersey Department of Health Recognizes National Infant Immunization Week

Trenton, NJ, April 23, 2017 — The New Jersey Department of Health and local health partners are promoting the importance of protecting infants from vaccine-preventable diseases during National Infant Immunization Week (NIIW) with events across the state.

NIIW, an annual observance highlighting the achievements of immunization programs and partners in promoting healthy communities, will be celebrated April 22 through 29.

“The best way to protect infants from 14 serious childhood diseases, like whooping cough and measles, is to make sure they receive recommended immunizations,” Health Commissioner Cathleen D. Bennett said. “This week serves as a reminder for parents to be sure their child is up-to-date on all recommended vaccines.” Continue reading

NIH Co-funds First New HIV Vaccine Efficacy Study in Seven Years

aids-hiv-vaccineBethesda, MD, November 29, 2016 — The National Institutes of Health (NIH) yesterday announced that the first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.

The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.

HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day. Continue reading

Congressional Inaction on Zika Funding Likely to Delay Vaccine Testing

Congress Do NOTHINGWashington, DC, July 13, 2016 The New York Times reports that the Obama administration on Tuesday cautioned top lawmakers that continued gridlock over legislation to combat the Zika virus could delay research and development of a vaccine to protect against Zika and tests to detect it.

The warning came in a letter from White House budget chief Shaun Donovan and Health and Human Services Secretary Sylvia Burwell and says that failure by Congress to pass anti-Zika funds before exiting Washington for its extended summer recess would “significantly impede the administration’s ability to prepare for and respond” to the Zika threat this summer and beyond. Continue reading

FDA Approves First Experimental Zika Vaccine to Begin Human Testing

Vaccine kidWashington, DC, June 21, 2016 — The Associated Press reports that an experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials.

Inovio Pharmaceuticals said Monday it received clearance from the Food and Drug Administration to begin early-stage safety tests of its DNA-based vaccine against the mosquito-borne virus.  That puts the company ahead of researchers at the National Institutes of Health, who have said they expect to begin testing their own DNA-based Zika vaccine by early fall.

Inovio’s vaccine is intended to prime the immune system to fight Zika by introducing genetically-engineered material that mimics the virus.  Inovio reports that animals tested with the vaccine developed antibodies and immune-system cells that attack Zika. Continue reading